Novo Nordisk Claims Oral Wegovy Outperforms Lilly’s Orforglipron in Key Metrics

Novo Nordisk has announced that its oral formulation of Wegovy (semaglutide) demonstrated superior performance compared to Eli Lilly’s competing drug, orforglipron, in key measures of efficacy and tolerability. The pharmaceutical giant released new analyses derived from the Orion indirect treatment comparison and the Optic patient preference studies. These studies specifically compared the effects of 25-milligram oral semaglutide against 36-milligram orforglipron. According to Novo Nordisk, the oral version of Wegovy resulted in greater average weight loss for patients and exhibited lower odds of adverse events, indicating better treatment tolerability. This development highlights the intensifying competition in the GLP-1 weight loss medication market, where both companies are vying for dominance with oral alternatives to their injectable treatments. The findings suggest a potential competitive advantage for Novo Nordisk in the emerging sector of oral obesity treatments, potentially influencing market share and patient preference in the future.